Physician profile
Catherine Joyce
NPI 1265850218
$2,611.16
in general payments reported to CMS, 2019-2025
19 companies · $693 in 2025
The $693 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.29 · 2022: $273 · 2023: $789 · 2024: $811 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,292.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $678.39 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $531.46 | 2021-2025 | |
| Pfizer INC. | $488.50 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.79 | 2022-2025 | Xifaxan |
| Exact Sciences Corporation | $178.15 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $109.42 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $104.90 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astrazeneca Pharmaceuticals LP | $56.49 | 2023-2024 | Breztri, Farxiga |
| Phadia US INC. | $35.53 | 2023-2025 | Immunocap |
| Amgen INC. | $32.28 | 2025 | Repatha |
| Csl Behring | $30.47 | 2024 | Haegarda |
| Antares Pharma, INC. | $27.05 | 2024 | Xyosted |
| Horizon Therapeutics Plc | $26.37 | 2023 | Krystexxa |
| Halozyme INC | $23.44 | 2023 | |
| Seqirus USA INC | $21.22 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $14.68 | 2021 | |
| Amarin Pharma, INC. | $14.09 | 2021 | |
| Lilly USA, LLC | $13.76 | 2025 | Zepbound, Mounjaro |
| Sanofi Pasteur INC. | $13.17 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Joyce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.